Women who have undergone breast augmentation surgery may have a higher risk of developing a rare form of breast cancer known as anaplastic large cell lymphoma (ALCL) according to the World Health Organization, the FDA and Health Canada.
In the United States, the FDA issued an initial warning regarding the risks of ALCL for women with breast implants in 2011. Here in Canada, Health Canada has also issued an alert and performed a Safety Review that links breast implants (especially so-called ‘textured implants’) with anaplastic large cell lymphoma. This disease has been designated as “breast implant-associated ALCL” or BIA-ALCL by the World Health Organization.
Globally there have been at least 440 confirmed cases of BIA-ALCL including 16 deaths. In Canada, there have been at least 5 confirmed cases of BIA-ALCL, 4 of which were associated with textured implants. These textured implants are only sold by three manufacturers – Mentor, Allergan Inc. and Ideal Implant Inc./Clarion Medical Technologies in Canada.
Thomson, Rogers is Investigating ALCL Cases on behalf of Victims
The law firm of Thomson, Rogers has recently been retained to investigate the possibility of claims, including a possible class action claim, against the manufacturers of breast implants, on behalf of women that have developed ALCL.
Thomson, Rogers is currently working with an ALCL cancer survivor who was diagnosed with this rare form of cancer in the summer of 2016 after she received Allergan textured breast implants several years earlier. As a result of her diagnosis, she was forced to undergo surgery and intensive radiation therapy that has left her with permanent disfigurement.
If you or a loved one has undergone a breast augmentation and have now been diagnosed with ALCL, please contact us for a free consultation about your rights by emailing Darcy Merkur (email@example.com) or calling 416-868-3176.
ALCL Symptoms and Treatment
BIA-ALCL usually develops in a capsule that surrounds the breast implants. BIA-ALCL typically presents with the following symptoms:
- Persistent or sudden swelling of the breast
- Breast pain in the vicinity of the implant
- Lump(s) in the breast or armpit
- Fluid Buildup
- Marked breast asymmetry
BIA-ALCL most often presents as delayed swelling of the breast years after the original surgery. On average, symptoms present 8 years post insertion of the implants but diagnoses have been made between 2 and 28 years after the implantation of textured implants.
If you have received textured breast implants and are experiencing the above symptoms, we urge you to seek medical treatment.
The majority of early-stage ALCL patients are treated by way of a total capsulectomy (that is a complete removal of the implant and surrounding scar tissue capsule). Although many women who receive an ALCL diagnosis and undergo a total capsulectomy do not require additional cancer treatment; chemotherapy and radiation therapy are frequently recommended if the cancer is more advanced or if it is suspected to have spread beyond the capsule. Many, if not all, of the women who receive capsulectomies, are not eligible for further breast reconstruction.
If you or a loved one in Canada has been diagnosed with BIA-ALCL, we urge you to contact us and request to speak with Darcy Merkur or another member of our class action department to discuss your legal rights.